RECORD 05 / QUERY INDEX
BPC-157 TB-500 FAQ
Twenty-one questions on the Wolverine blend, answered directly from the published record — definition, mechanism, evidence, dosing context, safety, and regulatory status.
Definition and naming
The questions below are answered from the published research record on BPC-157 TB-500 and from FDA primary sources. Each answer leads with the direct answer; quantitative claims cite a study in the full reference list.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 (a cytoprotective, angiogenic pentadecapeptide) and TB-500 (the Ac-LKKTETQ actin-binding fragment of Thymosin Beta-4). It is not a single chemical entity or an approved product — just two distinct molecules co-marketed as a tissue-repair stack.
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4. The blend pairs the two; the value gap is that most "TB-500" data are from full-length Thymosin Beta-4 [4].
What is the BPC-157 and TB-500 blend used for in research?
It is studied in animal models of tissue repair — tendon, ligament, muscle, and wound healing — with BPC-157 supplying a cytoprotective and pro-angiogenic signal [1][2] and TB-500 / Thymosin Beta-4 supplying a cytoskeletal cell-migration signal [3][4]. These are research contexts, not approved human uses.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157's VEGFR2-Akt-eNOS angiogenesis and cytoprotection [2] alongside TB-500 / Thymosin Beta-4's G-actin sequestration and cell migration [3][4]. This complementarity is theoretical — no controlled combination study has demonstrated it outperforms either peptide alone [9].
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No published controlled study defines a synergy ratio, dose, or endpoint for the two given together [9]. The "better together" claim extrapolates from each peptide's independently characterized mechanism [2][3]. The only human-tier data in the lineage are single-agent Phase 1 studies of full-length Thymosin Beta-4 [5][6].
Are there human clinical trials on the BPC-157 + TB-500 combination?
No. There are no controlled clinical trials of the combination for any indication [9]. Human data exist only for the individual constituents and are thin: three small BPC-157 pilot studies, plus Phase 1 safety and PK data for full-length Thymosin Beta-4 [5][6] — not the TB-500 fragment.
Is the 'Wolverine' synergy claim actually proven?
No. "Synergy" is a theoretical extrapolation from each peptide's separate, largely non-overlapping mechanism. No peer-reviewed study defines a synergistic dose, ratio, or endpoint, and the 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [7][9].
What do doctors and reviews say about the BPC-157 + TB-500 blend?
Recent reviews conclude the evidence is largely preclinical and low-tier: a 2025 systematic review rated BPC-157 level IV-V with "no clinical safety data" [7], and a 2026 Sports Medicine review found favorable animal-model repair but scarce human safety data and serious-harm potential for unapproved peptides [8]. Combination data are absent [9].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
In animal models, BPC-157 accelerated healing of transected rat Achilles tendon across biomechanical and microscopic measures [1], and Thymosin Beta-4 supports the migration and angiogenesis steps of repair [4]. These are preclinical findings for the individual compounds, not human evidence for the blend [9].
Does BPC-157 and TB-500 help muscle tears and recovery?
Preclinical and review evidence describes musculoskeletal-repair activity for BPC-157 and migration/regeneration roles for Thymosin Beta-4 [4]. A 2025 systematic review rates the BPC-157 musculoskeletal evidence at level IV-V — the lowest tiers [7]. No human combination data exist [9].
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, regulating the actin dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3][4]. The structural basis was established by crystallography of a Thymosin Beta-4-actin complex [3].
How does BPC-157 work compared to TB-500?
BPC-157 acts mainly extracellularly as a cytoprotective, pro-angiogenic signal — up-regulating VEGFR2 with downstream Akt-eNOS and growth-hormone-receptor effects [2] — while TB-500 acts on the intracellular cytoskeleton via G-actin sequestration [3]. The pathways are described as complementary and largely non-overlapping [4].
What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, nor for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study [9]; human IV full-length Thymosin Beta-4 showed dose-proportional PK with no specific half-life established for the TB-500 heptapeptide [5][6].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated; a common practice is to reconstitute the two separately or in a shared vial. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [9]. This describes laboratory handling, not human-use guidance.
How often should you inject BPC-157 and TB-500?
There is no validated dose or schedule for the blend. Community "loading then maintenance" protocols and fixed-ratio vials (e.g. 10 mg + 10 mg) have no controlled-trial basis [9]. The underlying animal studies used per-body-weight doses by routes (often intraperitoneal) that do not translate to human guidance [1][9].
What are the side effects of BPC-157 and TB-500?
Human safety data for the blend do not exist. Reviews describe both peptides as investigational with limited human safety data [7][8]; a theoretical tumor/angiogenesis concern attaches to Thymosin Beta-4 [4]. Findings are reported in research animals and single-compound human pilots, not as human safety guidance for the combination [9].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a recognized safety consideration, more so when two pro-repair peptides are combined [4]. This is a theoretical concern from preclinical literature, not a human finding for the blend [9].
Is Wolverine (BPC-157 + TB-500) legal?
Neither component is FDA-approved, and the blend has no approved therapeutic indication. Both BPC-157 and TB-500 are in FDA's 503A Category 2 — bulk substances FDA identified as potentially presenting significant safety risks — so routine compounding access is currently restricted [10][11]. Both are on the July 23-24, 2026 PCAC agenda as bulks-list candidates under review [12].
Can you get BPC-157 from a compounding pharmacy?
Currently, access is restricted. BPC-157 sits in FDA's 503A Category 2, outside FDA's enforcement-discretion policy for compounding [10][11]. Lawful compounded access generally requires a licensed-prescriber evaluation (telehealth can be the front-end channel), a patient-specific prescription, and an ingredient eligible under 503A/503B rules — which Category 2 status currently blocks [13].
What is the FDA 503A status of Wolverine (BPC-157 + TB-500)?
Both constituents are in 503A Category 2, effective with FDA's September 29, 2023 nominated-substances update [11], and outside FDA's enforcement-discretion policy [10]. Both are scheduled for discussion at the July 23-24, 2026 PCAC meeting as 503A bulks-list candidates — a review, not a decision or reclassification [12].
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use; both sit in 503A Category 2 with restricted compounding access [10][11]. Both are WADA-prohibited — BPC-157 under the S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories. The blend has no approved therapeutic indication.